Cover Image
市場調查報告書

嗜中性白血球彈性酵素:開發中產品分析

Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365751
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
嗜中性白血球彈性酵素:開發中產品分析 Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 62 Pages
簡介

本報告提供以嗜中性白血球彈性酵素為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

嗜中性白血球彈性酵素 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Cantex Pharmaceuticals, Inc.
  • Chiesi Farmaceutici SpA
  • Kamada Ltd.
  • Polyphor Ltd.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0195TDB

Summary

Global Markets Direct's, 'Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Review, H1 2016', provides in depth analysis on Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted pipeline therapeutics.

The report provides comprehensive information on the Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37)
  • The report reviews Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Overview
  • Therapeutics Development
    • Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Products under Development by Stage of Development
    • Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Products under Development by Therapy Area
    • Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Products under Development by Indication
  • Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Products under Development by Companies
  • Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Products under Development by Universities/Institutes
  • Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Companies Involved in Therapeutics Development
    • Cantex Pharmaceuticals, Inc.
    • Chiesi Farmaceutici SpA
    • Kamada Ltd.
    • Polyphor Ltd.
  • Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Drug Profiles
    • alpha-1 proteinase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANV-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Brevenal - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CX-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • POL-6014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Polysaccharides to Inhibit P-Selectin and HLE for Age-Related Macular Degeneration - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 1 to Inhibit Neutrophil Elastase for Immunology, Oncology and Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 2 to Inhibit Neutrophil Elastase for Immunology, Oncology and Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Neutrophil Elastase for Respiratory Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Dormant Projects
  • Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Discontinued Products
  • Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Featured News & Press Releases
    • Jun 15, 2016: Shire and Kamada announce FDA approval of expanded label for self-infusion of Glassia for the treatment of emphysema due to severe AAT deficiency
    • May 25, 2016: Kamadas Alpha-1 Antitrypsin Now Available to Treat Graft-Versus-Host Disease on myTomorrows Early Access Platform
    • Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
    • Mar 28, 2016: Kamada Submits Marketing Authorization Application with the European Medicines Agency for its Proprietary Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency
    • Mar 02, 2016: New Patent Issued to Cantex Pharmaceuticals for Its Lead Product Candidate in the Treatment of Thrombocytopenia and Neutropenia
    • Jan 06, 2016: Kamada Reports Further Positive Interim Data from Phase 1/2 Study of its Alpha-1 Antitrypsin to Treat Graft Versus Host Disease
    • Dec 02, 2015: Kamada Provides Update on Alpha-1 Antitrypsin Development in Newly Diagnosed Type 1 Diabetes
    • Sep 01, 2015: Polyphor extends clinical development portfolio by advancing its inhaled elastase inhibitor POL6014 for lung diseases to Phase I
    • Jul 06, 2015: Kamada Announces Publication in Pediatric Diabetes
    • Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
    • Jun 01, 2015: Cantex Pharmaceuticals Announces Poster Presentation at ASCO 2015 Indicating Potential Efficacy of CX-01
    • May 18, 2015: Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting
    • May 06, 2015: Kamada to Present Key Results from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin During the American Thoracic Society 2015 International Conference
    • Apr 01, 2015: Kamada Receives Allowance for Key Canadian Patent for Large Scale Production and Use of Proprietary Alpha-1 Proteinase Inhibitor
    • Mar 23, 2015: Kamada Awarded European Orphan Drug Designation for Its Alpha-1 Antitrypsin to Treat Graft-versus-Host Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Cantex Pharmaceuticals, Inc., H1 2016
  • Pipeline by Chiesi Farmaceutici SpA, H1 2016
  • Pipeline by Kamada Ltd., H1 2016
  • Pipeline by Polyphor Ltd., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top